Literature DB >> 22346737

Clostridium: transmission difficile?

Stephan Harbarth1, Matthew H Samore.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22346737      PMCID: PMC3274498          DOI: 10.1371/journal.pmed.1001171

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


× No keyword cloud information.

Linked Research Article

This Perspective discusses the following new study published in PLoS Medicine: Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, et al. (2012) Characterisation of Clostridium difficile Hospital Ward–Based Transmission Using Extensive Epidemiological Data and Molecular Typing. PLoS Med 9(2): e1001172. doi:10.1371/journal.pmed.1001172 A population-based study in Oxfordshire (UK) hospitals by Sarah Walker and colleagues finds that in an endemic setting with good infection control, ward-based contact cannot account for most new cases of Clostridium difficile infection.

Clostridium difficile Infection: Difficult to Control?

Clostridium difficile can cause large-scale outbreaks of diarrhea [1],[2]. Significant progress has recently been achieved to improve treatment of symptomatic C. difficile disease [3]. But hospitals affected by C. difficile infection still face challenges in the effort to control endemic C. difficile infections, which may be related to overuse of antibiotics (e.g., fluoroquinolones, cephalosporins), problems in cleaning services, and poor isolation practices [4],[5]. Furthermore, current diagnostic tests for C. difficile are not sensitive enough [6] and diagnosis can be delayed [7]. Evidence for the rate of nosocomial acquisition of C. difficile and the likelihood of within-hospital transmission from patients to patients of C. difficile infection remains scarce, so an improved evidence base could help improve infection control strategies [8]. Only a few studies have examined in detail the prevalence of C. difficile in hospital patients upon admission and nosocomial transmission rates of C. difficile infection [9]. For instance, 15 years ago, Samore et al. reported that for most epidemiologically linked contacts of C. difficile cases, positive cultures for C. difficile did not result from transmission from the presumed index case [8]. However, this and other studies were conducted before the emergence of new hypervirulent C. difficile strains and might not reflect the current epidemiology of C. difficile transmission.

Clostridium difficile Infection: Difficult to Transmit?

In a new study published in this issue of PLoS Medicine, Sarah Walker and colleagues examine the epidemiology of C. difficile infection, focusing on the role of within-hospital transmission among ward patients. The investigators used a simplified model that was populated with observational data from one National Health Service (NHS) Hospital Trust in the United Kingdom, a country that introduced compulsory surveillance with mandatory C. difficile testing of all elderly inpatients with diarrhea in 2008 [10]. Surprisingly, based on the results of their network analysis combined with molecular strain typing, up to three-quarters of patients with C. difficile infection did not acquire their infecting C. difficile strain during their hospital stay. Using time intervals, strain types, and patient location as plausibility checks, the authors propose that within-hospital transmission accounted for a relatively small number of the overall C. difficile cases detected. However, the rates of transmission varied in different specialty wards, with renal and transplant wards having the highest documented rates. Most of the cases of C. difficile that were attributed to within-hospital transmission occurred shortly after the onset of symptoms of the index case, suggesting that the hospital environment was not, as has previously been claimed, a long-lasting reservoir for this pathogen [7]. Overall, this study suggests that alternative explanations need to be sought for the origin of most of the new onset cases of C. difficile infection.

Moving On—What Do We Need to Know Next about C. difficile Transmission?

This impressive study addresses an important question—to what extent can we control C. difficile infection by prevention of transmission from symptomatic C. difficile infection cases in hospitals? However, there are limitations to the approach chosen in this study, including several possible sources of bias already mentioned by the authors (e.g., selection, misclassification, and information biases). Other potential limitations not considered in this study include the possibility of inter-ward transmission. Patients from different wards might, for instance, be transported to common sectors of the hospital for procedures and diagnostic tests, e.g., X-rays. Potential vectors of transmission, including equipment and health care workers who might care for patients on different wards, could be similarly mobile. In this study, wards were small relative to the hospital size. It is likely that, on average, many more symptomatic C. difficile cases were housed on “other” wards than on the “same” ward. Even though rates of intra-ward transmission per infected case were probably significantly higher than rates of inter-ward transmission per infected case, the absolute number of inter-ward transmissions may have, in fact, exceeded the number of intra-ward transmissions. Second, the poor sensitivity of the Enzyme Immuno-Assay (EIA) testing method for C. difficile diagnosis may have ignored a potentially significant pool of undiagnosed C. difficile patients (which could have been selected as controls, introducing misclassification bias). Third, antibiotic exposure data were not recorded, which could have biased the dates of onset of symptoms and cross-transmission. Finally, transmission events linked to asymptomatic carriers were not routinely detected [11].

Practical Implications

The two key practical questions related to this study are 1) how much benefit is accrued by blocking transmission from symptomatic C. difficile infection cases; 2) what proportion of the C. difficile infections that are attributed to within-hospital transmission instead represent already-infected individuals who come into the hospital carrying toxigenic C. difficile strains in their gut flora. The study by Sarah Walker and colleagues cannot provide definitive answers to these questions because it has significant limitations with respect to both issues. The study cannot answer question 1, about benefit accrued by blocking C. difficile transmission, because it did not examine inter-ward transmission. Further, it cannot tell us how many patients came in already colonized or infected because it did not examine asymptomatic C. difficile carriage upon admission and discharge. Attempting to interpret the results of this study with respect to these practical issues highlights the need to utilise models that account for the non-linear dynamics of spread of C. difficile.

Future Studies

Further studies are needed to elucidate answers to the two key questions we have identified above. Investigations should examine the possibility of transmission from falsely EIA-negative symptomatic patients, asymptomatic carriers (patients or health care workers), and community acquisition with importation of C. difficile into the hospital setting [12], and this might require both more data and the use of more advanced transmission models such as hidden Markov models. More detailed screening data, such as a study that reported screening of asymptomatic C. difficile carriers in a large prospective cohort [13], and new models will help to answer the question of whether C. difficile is less of an institutional and more of a community problem than has previously been thought. Proving that the majority of nosocomial C. difficile infections are actually imported into hospitals (with toxigenic C. difficile strains being already present on admission) would be “revolutionary”—however, we believe that the evidence generated by this study, albeit tantalizing, is not yet sufficient to prove this hypothesis.
  13 in total

1.  Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Chris Funston; Karen Savage; Denise Kelly; Motasem A Aldiab; James C McElnay
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

2.  Clostridium difficile infection.

Authors:  Ernst J Kuipers; Christina M Surawicz
Journal:  Lancet       Date:  2008-05-03       Impact factor: 79.321

Review 3.  Use of benchmarking and public reporting for infection control in four high-income countries.

Authors:  Thomas Haustein; Petra Gastmeier; Alison Holmes; Jean-Christophe Lucet; Richard P Shannon; Didier Pittet; Stephan Harbarth
Journal:  Lancet Infect Dis       Date:  2011-06       Impact factor: 25.071

4.  Clostridium difficile infection in Europe: a hospital-based survey.

Authors:  Martijn P Bauer; Daan W Notermans; Birgit H B van Benthem; Jon S Brazier; Mark H Wilcox; Maja Rupnik; Dominique L Monnet; Jaap T van Dissel; Ed J Kuijper
Journal:  Lancet       Date:  2011-01-01       Impact factor: 79.321

5.  Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures.

Authors:  Mamoon A Aldeyab; Michael J Devine; Peter Flanagan; Michael Mannion; Avril Craig; Michael G Scott; Stephan Harbarth; Nathalie Vernaz; Elizabeth Davies; Jon S Brazier; Brian Smyth; James C McElnay; Brendan F Gilmore; Geraldine Conlon; Fidelma A Magee; Feras W Darwish Elhajji; Shaunagh Small; Collette Edwards; Chris Funston; Mary P Kearney
Journal:  Infect Control Hosp Epidemiol       Date:  2011-03       Impact factor: 3.254

6.  Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea.

Authors:  J K Shim; S Johnson; M H Samore; D Z Bliss; D N Gerding
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

7.  Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.

Authors:  Michelle M Riggs; Ajay K Sethi; Trina F Zabarsky; Elizabeth C Eckstein; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

8.  Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea.

Authors:  M H Samore; L Venkataraman; P C DeGirolami; R D Arbeit; A W Karchmer
Journal:  Am J Med       Date:  1996-01       Impact factor: 4.965

9.  Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors.

Authors:  S B Debast; N Vaessen; A Choudry; E A J Wiegers-Ligtvoet; R J van den Berg; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2009-03-23       Impact factor: 8.067

10.  Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Authors:  Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

View more
  4 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Diverse sources of C. difficile infection identified on whole-genome sequencing.

Authors:  Derrick W Crook; Mark H Wilcox; Tim E A Peto; A Sarah Walker; David W Eyre; Madeleine L Cule; Daniel J Wilson; David Griffiths; Alison Vaughan; Lily O'Connor; Camilla L C Ip; Tanya Golubchik; Elizabeth M Batty; John M Finney; David H Wyllie; Xavier Didelot; Paolo Piazza; Rory Bowden; Kate E Dingle; Rosalind M Harding
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

3.  Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.

Authors:  Dilip Nathwani; Oliver A Cornely; Anke K Van Engen; Olatunji Odufowora-Sita; Peny Retsa; Isaac A O Odeyemi
Journal:  J Antimicrob Chemother       Date:  2014-08-05       Impact factor: 5.790

4.  Low frequency of asymptomatic carriage of toxigenic Clostridium difficile in an acute care geriatric hospital: prospective cohort study in Switzerland.

Authors:  Daniela Pires; Virginie Prendki; Gesuele Renzi; Carolina Fankhauser; Valerie Sauvan; Benedikt Huttner; Jacques Schrenzel; Stephan Harbarth
Journal:  Antimicrob Resist Infect Control       Date:  2016-06-08       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.